Shed将 Foundayo™添加到其平台，扩大了全国患者对口服 GLP-1的获取途径

Eli Lilly's newly FDA-approved once-daily weight loss pill now available through Shed's patient-centered care platform

礼来公司新获FDA批准的每日一次减肥药现已通过Shed的以患者为中心的护理平台提供。

SALT LAKE CITY

盐湖城

,

，

April 15, 2026

2026年4月15日

/PRNewswire/ -- Shed, a leading online health and wellness platform, today announced it is now offering Foundayo™ (orforglipron), Eli Lilly and Company's FDA-approved once-daily oral

/PRNewswire/ -- Shed，领先的在线健康与保健平台，今天宣布现在提供 Foundayo™（orforglipron），这是礼来公司获得 FDA 批准的每日一次口服药物。

GLP-1

GLP-1

therapy for weight management. The addition gives Shed members a clinically proven, needle-free alternative to injectable

体重管理的治疗。这一补充为Shed会员提供了一种经过临床验证、无需注射的替代方案。

GLP-1

GLP-1

treatments — one that requires no special meal timing and fits naturally into everyday life.

治疗方法——一种不需要特殊饮食时间安排，并能自然融入日常生活的方法。

Continue Reading

继续阅读

Shed Adds Foundayo™ to Its Platform, Expanding Oral GLP-1 Access for Patients Nationwide

Shed将其平台添加了Foundayo™，扩大了全国患者对口服GLP-1药物的获取途径。

Foundayo is indicated for adults with obesity, or adults who are overweight with at least one weight-related health condition, and is intended to be used alongside a reduced-calorie diet and increased physical activity. In clinical trials, patients using the highest dose achieved an average weight loss of 12.4% of their body weight at 72 weeks.¹.

Foundayo 适用于患有肥胖症的成年人，或超重且至少有一种与体重相关的健康状况的成年人，建议与减少热量的饮食和增加体力活动一起使用。在临床试验中，使用最高剂量的患者在72周时平均减重了其体重的12.4%。¹

'Expanding access to therapies like Foundayo reflects our commitment to offering the most complete wellness journey possible,' said Morley Baker, CEO of Shed. 'For patients who have wanted the benefits of a

“扩大像Foundayo这样的疗法的使用范围，体现了我们致力于提供尽可能完整的健康旅程，”Shed首席执行官莫利·贝克表示。“对于那些希望获得好处的患者来说，

GLP-1

GLP-1

without the barrier of injections, this is a significant step forward.'

没有注射的障碍，这是一个重大的进步。

Shed's platform allows patients to complete a full evaluation online, connect with a licensed healthcare provider, and — if appropriate — receive a personalized treatment plan that may include Foundayo as part of a broader care strategy. The process is entirely online, with medications shipped directly to members' doors..

Shed的平台允许患者在线完成全面评估，联系有执照的医疗保健提供者，并且——如果合适的话——接收个性化的治疗计划，其中可能包括Foundayo作为更广泛护理策略的一部分。整个过程完全在线进行，药物直接配送到会员的家门口。

The addition of Foundayo builds on Shed's existing suite of

Foundayo 的加入建立在 Shed 现有的套件基础上

GLP-1

GLP-1

health solutions, reinforcing its position as a comprehensive destination for evidence-based weight loss and wellness care, further leaning into its mission to offer the most complete wellness journey.

健康解决方案，进一步巩固其作为基于证据的减肥和健康护理综合目的地的地位，更加坚定地履行其提供最完整健康旅程的使命。

Foundayo™ is now available to eligible patients through Shed. Visit to learn more.

Foundayo™ 现已通过 Shed 提供给符合条件的患者。访问 了解更多信息。

About Shed

关于棚屋

Shed is a modern health and wellness platform helping people feel their best — physically, mentally, and emotionally. Combining evidence-based treatments with personalized coaching, education, and ongoing provider support, Shed makes sustainable wellness simple and accessible. For more information, visit..

Shed 是一个现代健康与保健平台，帮助人们在身体、心理和情感上达到最佳状态。通过将基于证据的治疗与个性化辅导、教育及持续的专业支持相结合，Shed 让可持续的健康变得简单且易于获取。欲了解更多信息，请访问。

Important Safety Information

重要安全信息

Foundayo™ (orforglipron) is a prescription medicine. It may cause thyroid tumors, including thyroid cancer. Do not use if you or a family member have ever had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The most common side effects include nausea, diarrhea, constipation, and vomiting.

Foundayo™（orforglipron）是一种处方药。它可能会导致甲状腺肿瘤，包括甲状腺癌。如果您或您的家人曾经患有甲状腺髓样癌 (MTC) 或 2 型多发性内分泌腺瘤病 (MEN 2)，请勿使用。最常见的副作用包括恶心、腹泻、便秘和呕吐。

Foundayo should not be used with other .

Foundayo 不应与其他药物同时使用。

GLP-1

GLP-1

receptor agonist medicines. Always consult a licensed healthcare provider to determine if Foundayo is appropriate for you. This is not a complete list of risks — please review the full Prescribing Information and Medication Guide.

受体激动剂药物。始终请咨询有执照的医疗保健提供者，以确定Foundayo是否适合您。这并非完整的风险列表 — 请查阅完整的处方信息和药物指南。

¹ Wharton S, et al. 'Orforglipron for Obesity.' New England Journal of Medicine. 2025. doi:10.1056/NEJMoa2511774. Results from the Phase 3 ATTAIN-1 trial in adults with obesity without type 2 diabetes. Highest dose (36 mg capsule equivalent); average weight loss of 12.4% at 72 weeks using the efficacy estimand.

¹ Wharton S, 等。《Orforglipron用于肥胖症》。《新英格兰医学杂志》，2025年。doi:10.1056/NEJMoa2511774。来自ATTAIN-1三期临床试验的结果，针对不伴有2型糖尿病的成年肥胖患者。最高剂量（相当于36毫克胶囊）；在72周时使用疗效估算指标，平均体重减轻12.4%。

Individual results may vary..

个体结果可能有所不同。

Shed is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company. Foundayo™ is a trademark of Eli Lilly and Company. Shed is an independent telehealth platform that offers access to FDA-approved medications, including those manufactured by third parties, through licensed healthcare providers..

Shed与Eli Lilly and Company无关联、未获其认可或赞助。Foundayo™是Eli Lilly and Company的商标。Shed是一个独立的远程医疗平台，通过持牌医疗保健提供者提供对FDA批准的药物的访问，包括由第三方制造的药物。

Media Contact:

媒体联系人：

Jamie Neider

杰米·奈德

8015205785

8015205785

[email protected]

电子邮件地址

SOURCE Shed

源码库

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示